VACCINES AGAINST CHLAMYDIA TRACHOMATIS

Team Members

Samantha D. Armijo

Andzoa N. Jamus

Zoe E. Wilton

Amanda L. Collar

Tegan N. Clarke

We are using virus-like particles (VLPs) derived from small RNA bacteriophages as antigen-display platforms for Chlamydia trachomatis vaccines.  We identify antigens of interest that are important for Chlamydia trachomatis infection, display them on VLPs using a variety of molecular biology techniques, and then test them for their immunogenicity and ability to elicit antibodies that can block Chlamydia trachomatis infection. 

Funding

NIH/NIAID R01AI166360, to Kathryn Frietze

NIH/NIAID U19AI113187, EPIC-STI NIAID Cooperative Research Center 

NIH/NIAID F30 Fellowship to Amanda L. Collar

NIH/NIAID T32 Pre-Doctoral Fellowship to Amanda L. Collar

NIH/NIAID T32 Pre-Doctoral Fellowship to Andzoa N. Jamus

University of New Mexico CTSC Pilot Award 2021 Kathryn M. Frietze